This is especially a concern for older adults. Researchers say that taking the obesity medication liraglutide and exercising regularly can lead to weight loss — and bone health is still maintained.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

The drug, liraglutide, is sold under the brand names Victoza and Saxenda. Liraglutide was not originally developed as a weight-loss treatment. Like semaglutide (Ozempic), it originally treated ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that ...

New study reveals semaglutide outperforms liraglutide in weight loss for obesity, highlighting key factors that contribute to significant weight reduction in patients. Study: One-Year Weight ...

We’re committed to bringing our customers more treatment options that best suit their needs, and we’ve now expanded that choice even further by adding access to generic liraglutide and branded ...

Lexaria Bioscience (LEXX) announced the engagement of a contract research organization to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda injectable ...

Liraglutide may help protect the brain, researchers found. Liraglutide appears to slow cognitive decline by protecting the brain, according to data from a mid-stage clinical trial revealed at the ...

Study reveals liraglutide's potential to regulate iron metabolism and improve glucose tolerance in a mouse model of hereditary hemochromatosis and obesity. Study: Liraglutide Impacts Iron ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®.

In patients with type 2 diabetes but usually not heart disease, liraglutide had better CV outcomes vs. some other therapies. Drugs linked to CV benefit may be appropriate for lower-risk patients ...